IL1B and Miyoshi myopathy: It is conceivable that the initial increase in IL-1β levels in response to chemotherapeutic drugs could be sufficient to start inflammasome-dependent signaling cascades so that the usage of interleukin-1 receptor antagonist (IL-1Ra; Anakinra) before chemotherapy could be a better strategy for MM tumor treatment [12].